4NLD
Crystal structure of the hepatitis C virus NS5B RNA-dependent RNA polymerase complex with BMS-791325 also known as (1aR,12bS)-8-cyclohexyl-n-(dimethylsulfamoyl)-11-methoxy-1a-{[(1R,5S)-3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl]carbonyl}-1,1a,2,12b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide and 2-(4-fluorophenyl)-n-methyl-6-[(methylsulfonyl)amino]-5-(propan-2-yloxy)-1-benzofuran-3-carboxamide
4NLD の概要
| エントリーDOI | 10.2210/pdb4nld/pdb |
| 分子名称 | RNA-directed RNA polymerase, (1aR,12bS)-8-cyclohexyl-N-(dimethylsulfamoyl)-11-methoxy-1a-{[(1R,5S)-3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl]carbonyl}-1,1a,2,12b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide, 2-(4-fluorophenyl)-N-methyl-6-[(methylsulfonyl)amino]-5-(propan-2-yloxy)-1-benzofuran-3-carboxamide, ... (6 entities in total) |
| 機能のキーワード | ns5b, polymerase, hcv, hepatitis c virus, fingers, palm, thumb, transferase/transferase inhibitor, polymerase/polymerase inhibitor, transferase-transferase inhibitor complex |
| 由来する生物種 | Hepatitis C virus (HCV) |
| タンパク質・核酸の鎖数 | 1 |
| 化学式量合計 | 66010.80 |
| 構造登録者 | |
| 主引用文献 | Gentles, R.G.,Ding, M.,Bender, J.A.,Bergstrom, C.P.,Grant-Young, K.,Hewawasam, P.,Hudyma, T.,Martin, S.,Nickel, A.,Regueiro-Ren, A.,Tu, Y.,Yang, Z.,Yeung, K.S.,Zheng, X.,Chao, S.,Sun, J.H.,Beno, B.R.,Camac, D.M.,Chang, C.H.,Gao, M.,Morin, P.E.,Sheriff, S.,Tredup, J.,Wan, J.,Witmer, M.R.,Xie, D.,Hanumegowda, U.,Knipe, J.,Mosure, K.,Santone, K.S.,Parker, D.D.,Zhuo, X.,Lemm, J.,Liu, M.,Pelosi, L.,Rigat, K.,Voss, S.,Wang, Y.,Wang, Y.K.,Colonno, R.J.,Gao, M.,Roberts, S.B.,Gao, Q.,Ng, A.,Meanwell, N.A.,Kadow, J.F. Discovery and Preclinical Characterization of the Cyclopropylindolobenzazepine BMS-791325, A Potent Allosteric Inhibitor of the Hepatitis C Virus NS5B Polymerase. J.Med.Chem., 57:1855-1879, 2014 Cited by PubMed Abstract: Described herein are structure-activity relationship studies that resulted in the optimization of the activity of members of a class of cyclopropyl-fused indolobenzazepine HCV NS5B polymerase inhibitors. Subsequent iterations of analogue design and syntheses successfully addressed off-target activities, most notably human pregnane X receptor (hPXR) transactivation, and led to significant improvements in the physicochemical properties of lead compounds. Those analogues exhibiting improved solubility and membrane permeability were shown to have notably enhanced pharmacokinetic profiles. Additionally, a series of alkyl bridged piperazine carboxamides was identified as being of particular interest, and from which the compound BMS-791325 (2) was found to have distinguishing antiviral, safety, and pharmacokinetic properties that resulted in its selection for clinical evaluation. PubMed: 24397558DOI: 10.1021/jm4016894 主引用文献が同じPDBエントリー |
| 実験手法 | X-RAY DIFFRACTION (2.75 Å) |
構造検証レポート
検証レポート(詳細版)
をダウンロード






